Oxford Cancer Biomarkers
PrivateLast Round
VC Round
Apr 3, 2023
Est. Valuation
$15.67M
Total Funding Raised
$6.47M
Company Overview
Oxford Cancer Biomarkers is a biotechnology company that develops and commercializes AI-driven, precision cancer diagnostic tests.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oxford Cancer Biomarkers Comparables
Compare Oxford Cancer Biomarkers with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novacyt S.A. | 79% | |
| EntroGen, Inc. | 77% | |
| Myriad Genetics | 76% |
Oxford Cancer Biomarkers Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 3, 2023 | ||||
| Grant | Mar 3, 2023 | ||||
| VC Round | Dec 14, 2015 | ||||
| Series A | Jan 18, 2012 |
Oxford Cancer Biomarkers Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Plutus Investment Group | VC Round |
| Department of Health and Social Care | Grant |
| University of Oxford | Series A |
| NHS AI Lab | Grant |
| Longwall Venture Partners | VC Round |
| National Institute for Health and Care Research | Grant |
| Oxford Technology | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors grew 50% MoM, reaching 1.3K.
- Apr 20, 2026
Monthly visitors grew 333% MoM, from 204 to 883.
Oxford Cancer Biomarkers Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Oxford Cancer Biomarkers's valuation, stock price, and market status.
Is Oxford Cancer Biomarkers a public or private company?
Oxford Cancer Biomarkers is a private company.
What is the current stock price of Oxford Cancer Biomarkers?
Oxford Cancer Biomarkers is a private company, so its shares have no public market price. Caplight tracks Oxford Cancer Biomarkers's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oxford Cancer Biomarkers worth (valuation)?
Oxford Cancer Biomarkers's valuation is estimated at $15.7M based on funding round data.
Can I buy Oxford Cancer Biomarkers stock?
Oxford Cancer Biomarkers shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oxford Cancer Biomarkers's last funding round?
Oxford Cancer Biomarkers's most recent funding round was VC Round on April 3, 2023.
Who are the main investors in Oxford Cancer Biomarkers?
Key investors in Oxford Cancer Biomarkers include Plutus Investment Group.
Will Oxford Cancer Biomarkers IPO soon?
No public IPO plans have been announced for Oxford Cancer Biomarkers.
How can I track Oxford Cancer Biomarkers secondary market activity?
Caplight tracks bids, offers, and trades in Oxford Cancer Biomarkers's shares on secondary markets.